Exosome Diagnostics, Inc., the developer of a revolutionary liquid biopsy platform that enables non-invasive diagnosis of serious diseases, aiming to reduce or eliminate the need for tissue biopsies, ...
Baltimore, Md. and Boston, Ma., Aug. 24, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Exosome Diagnostics, Inc. (ExoDx) announced today that they have signed an agreement to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., the world’s only provider of a revolutionary liquid biopsy platform that enables analysis of both living and dying processes of disease ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, the developer of the leading liquid biopsy platform that enables non-invasive diagnosis of disease states, aiming to obviate the need for tissue ...
WASHINGTON and NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical ...
The "Exosome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ResearchAndMarkets.com's offering. The Global Exosome Therapeutics Market, ...
The exosome diagnostic and therapeutic market was valued at US$ 41.6.33 million in 2019 and is expected to grow at a CAGR of 32.2% from 2020 to 2027 to reach US$ 358.91 million 2027. According to The ...
Liquid biopsy player Exosome Diagnostics is partnering with CareFirst BlueCross BlueShield to create evidence development studies for the evaluation of its EvoDx tests. The agreement is part of ...
Waltham, MA, March 21, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., is thrilled to announce the appointment of Dr. Grannum Sant as Head of Medical Affairs. As an internationally recognized ...
MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract ...
Minneapolis-based biotech supplier Bio-Techne Corp. has agreed to pay $250 million, and maybe more, to acquire a promising Boston-area firm that makes precision-medicine technology used to detect ...
Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback